anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Controversies remain on the diagnostic strategy in suspected AA, considering the different settings worldwide.
MATERIAL AND METHODS: A prospective observational international multicentric study including patients operated for suspected AA with a definitive histopathological analysis was conducted. Three groups were analyzed: (1) No radiology; (2) Ultrasound, and (3) Computed tomography. The aim was to analyze the performance of three diagnostic schemes.
RESULTS: Three thousand and one hundred twenty three patients were enrolled; 899 in the no radiology group, 1490 in the US group, and 734 in the CT group. The sex ratio was in favor of males (p < 0.001). The mean age was lower in the no radiology group (24 years) compared to 28 and 38 years in US and CT-scan groups, respectively (p < 0.001). Overall, the negative appendectomy rate 3.8%: no radiology group (5.1%) versus US (2.9%) and CT-scan (4.1%) (p < 0.001). The sensitivity and specificity analysis showed the best balance in clinical evaluation + score + US. These data reach the best results in those patients with an equivocal Alvarado score (4-6). Inverse probability weighting (IPW), showed as the use of ultrasound, is significantly associated with an increased probability of formulating the correct diagnosis (p 0.004). In the case of a CT scan, this association appears weaker (p 0.08).
CONCLUSION: The association of clinical scores and ultrasound seems the best strategy to reach a correct preoperative diagnosis in patients with clinical suspicion of AA, even in those population subgroups where the clinical score may have an equivocal result. This strategy can be especially useful in low-resource settings worldwide. CT-scan association may improve the detection of patients who may potentially be submitted to conservative treatment.
Hepatic fibrosis is a common pathological process in chronic liver diseases, characterized by excessive reactive oxygen species (ROS), activated hepatic stellate cells (HSCs), and massive synthesis of extracellular matrix (ECM), which are important factors in the development of liver cirrhosis, liver failure, and liver cancer. During the development of hepatic fibrosis, ECM collagen produced by activated HSCs significantly hinders medication delivery to targeted cells and reduces the efficiency of pharmacological therapy. In this study, we designed a multifunctional hyaluronic acid polymeric nanoparticle (HA@PRB/COL NPs) based on autophagy inhibitor probucol (PRB) and collagenase type I (COL) modification, which could enhance ECM degradation and accurately target HSCs through specificity binding CD44 receptor in hepatic fibrosis therapy. Upon encountering excessive collagen I-deposition formed barrier, HA@PRB/COL NPs performed the nanodrill-like function to effectively degrade pericellular collagen I, leading to greater ECM penetration and prominent HSCs internalization capacity of delivered PRB. In mouse hepatic fibrosis model, HA@PRB/COL NPs were efficiently delivered to HSCs through binding CD44 receptor to achieve efficient accumulation in fibrotic liver. Further, we showed that HA@PRB/COL NPs executed the optimal anti-fibrotic activity by inhibiting autophagy and activation of HSCs. In conclusion, our novel dual-functional co-delivery system with degrading fibrotic ECM collagen and targeting activated HSCs exhibits great potentials in the treatment of hepatic fibrosis in clinic. STATEMENT OF SIGNIFICANCE: The excess release of extracellular matrix (ECM) such as collagen in hepatic fibrosis hinders medication delivery and decreases the efficiency of pharmacological drugs. We aimed to develop a nano-delivery carrier system with protein hydrolyzed surfaces and further encapsulated an autophagy inhibitor (PRB) to enhance fibrosis-related ECM degradation-penetration and hepatic stellate cells (HSCs) targeting in hepatic fibrosis niche (HA@PRB/COL NPs). The COL of HA@PRB/COL NPs successfully worked as a scavenger to promote the digestion of the ECM collagen I barrier for deeper penetration into fibroid liver tissue. It also accurately targeted HSCs through specifically binding to the CD44 receptor and subsequently released PRB to inhibit autolysosome and ROS generation, thus preventing HSCs activation. Our HA@PRB/COL NPs system provided a promising therapeutic strategy for hepatic fibrosis in a clinic setting.
The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling.

The alcohol content of Cyclophosphamide Injection should be taken into account when given to pediatric patients [see Warnings and Precautions (5.7)].

Pre-pubescent girls treated with cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged cyclophosphamide treatment in late pre-pubescence has been reported. Girls treated with cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause.

Pre-pubescent boys treated with cyclophosphamide develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.
The first group of 26 volunteers who meet the inclusion criteria of the study will form the control group. These participants will be given clinical routine training about mucositis care.
The present invention is drawn to systems and methods for reducing unintended use of an active ingredient, such as residual active ingredients present in spent dermal patches and peels. The system can include a dermal patch including an active ingredient and a destructive agent configured to chemically react with the active ingredient. The destructive agent can be present in a container or an absorber. In one embodiment, the absorber can be used within the container. The container can be configured to receive the dermal patch such that the active ingredient contacts the destructive agent within the container. The absorber can be configured to contact the dermal patch such that the active ingredient contacts the destructive agent of the absorber. Additionally, systems and methods for impeding the unintended use of an active ingredient, such as those present in dermal patches or peels, are also provided. The system includes a dermal patch having a first side configured to deliver an active ingredient to a skin or mucosal surface, wherein the first side also includes a dermal adhesive. The system also includes an adhesive-coated device. The adhesive-coated surface of the device can be configured to adhere to the first side, wherein upon use of the dermal patch followed by contacting the adhesive-coated surface with the first side, residual active ingredient is rendered substantially inaccessible.
Objective: Photobiomodulation (PBM) is a noninvasive therapeutic modality with widespread applications for modulating various biological processes. Although the exact mechanisms of action remain uncertain, PBM promotes homeostasis through diverse pathways, including reducing inflammation and enhancing tissue recovery. Hearing loss is irreversible in mammals due to the limited regenerative capacity of cochlear hair cells. Cochlear implants offer a solution by electrically stimulating the auditory nerve, bypassing damaged hair cells in individuals with severe hearing loss. However, postoperative inflammatory responses and cochlear nerve fiber damage can compromise implant efficacy. Materials and Methods: We investigated current strategies to minimize secondary cochlear damage after cochlear implantation and evaluated the potential of PBM as an adjuvant therapeutic approach. Results: The auditory cell protective effects of PBM could significantly enhance the performance of EAS devices in individuals with residual hearing. Further, postoperative CI is accompanied by an inflammatory response characterized by the upregulation of specific cytokines. Conclusion: Considering the neuroregenerative potential of PBM, its application as a neuroprotective strategy warrants further validation.
Participants in the intervention group will receive protein-enriched soups (24-30g of protein) per day for 12 weeks. Protein may come from either soy, bean or milk products.
OBJECTIVE: Osteoarthritis (OA) is one of the major disabling human diseases. The related studies indicate a potential correlation between walking and OA. However, there is still a lack of evidence in genetics to support the correlation between walking and OA. Therefore, this study aimed to explore the relationship between walking and OA at the genetic level.
METHODS: The publicly available Genome Wide Association Study (GWAS) data were used, with inverse variance weighting (IVW, the random-effects model) as the main analysis method, whereas MR-Egger, Weighted median, Simple mode, and Weighted mode as the secondary analysis methods. In addition, Cochran's Q test, pleiotropy test, and MR-Egger intercept test were conducted to examine the heterogeneity and pleiotropy of the outcome.
RESULTS: In the MR analysis, IVW results showed a negative correlation between types of physical activity in last 4 weeks: Walking for pleasure (not as a means of transport) and OA (KOA or HOA) (odds ratio (OR) = 0.3224, 95% confidence interval (CI): 0.1261 to 0.8243), and the difference was of statistical significance (P = 0.0181). Moreover, IVW results also revealed a negative correlation between types of physical activity in last 4 weeks: Walking for pleasure (not as a means of transport) and KOA (OR = 0.1396, 95% CI: 0.0484 to 0.4026), and the difference was statistically significant (P = 0.0003). However, IVW results did not demonstrate any statistical significance types of physical activity in last 4 weeks: Walking for pleasure (not as a means of transport) and HOA (OR = 1.2075, 95% CI: 0.1978 to 7.3727, P = 0.8381).
CONCLUSION: From genetic studies, types of physical activity in last 4 weeks: Walking for pleasure (not as a means of transport) is negatively correlated with knee osteoarthritis (KOA), but there is no clear evidence supporting its correlation with hip osteoarthritis (HOA).
Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
The invention belongs to the technical field of animal model construction, and discloses application of lipopolysaccharide-mediated severe liver injury and a construction method of an animal model. The method comprises the following steps: (1) establishing a mouse model for severe liver injury of mice by using carbon tetrachloride with different doses. (2) Different doses of lipopolysaccharide induced liver injury and critical dose determination (less than 0.5 mg/kg; control model) for determining that no liver injury of mice is caused under normal physiological conditions. (3) A model construction and liver injury severe evaluation system of 0.1mg/kg lipopolysaccharide mediated carbon tetrachloride induced mouse liver injury severe. The method comprises the following steps: inducing the mice with carbon tetrachloride for 24h, and controlling with solvent olive oil; mice were post-induced with lipopolysaccharide, with PBS control; model mice induced by 1ml/kg carbon tetrachloride were intervened by 0.1 mg/kg. The invention lays an experimental foundation for researching the application of lipopolysaccharide-mediated animal model liver injury intensification and related mechanisms.
261,455. Landman, M. L. Aug. 7, 1925. Bacteria, cultivating; bacteria, preparations for administering; emulsions, making.-Therapeutic or other bacteria are prepared for storage and use by making an emulsion of an aqueous culture thereof and a mineral oil, the culture forming the disperse phase and the oil the continuous phase. In an example an aqueous solution of agar-agar is added in successive small quantities to medicinal paraffin so as to form an emulsion of the type referred to. A concentrated culture of bacillus acidophilus in milk or whey broth is then stirred in. The aqueous medium and the oil should be in substantially equal proportions in order that the emulsion formed may have the oil as the continuous phase and may be sufficiently fluid for convenient use. Emulsions of bacillus bulgaricus may also be prepared.
Patient information such as age, gender, history of periodontitis, edentulism, previous oral and maxillofacial tumor with a history of head and neck radiation, smoking habits, and metabolic diseases like diabetes mellitus were collected. Implant-specific information such as bone augmentation, year of implantation, implant position, implant level (bone level, tissue level), and number of implants were also documented. Prosthetic factors like the type of prosthesis (single crown, bridge construction, telescope prosthesis) and the type of attachment (cemented, screwed) were recorded. Clinical examination and measurement of clinical parameters were subsequently performed, including probing depth (PD) at six implant sites using a graduated periodontal probe, bleeding on probing or suppuration (BoP/Sup) occurring within 30 seconds after probing, and recessions measured in mm using a graduated periodontal probe between a defined clinical reference point and the implant mucosa.Participants were motivated to undergo regular SPIC, with frequency based on their individual risk factors. Patients without increased risk were encouraged to attend a 6-month recall. If bleeding or suppuration occurred, the frequency of SPIC was increased to monthly controls with oral hygiene instruction and plaque removal. Peri-implantitis therapy was initiated in patients with radiographically detectable bone loss, followed by lifelong SPIC. The modified plaque index (mPl) and full mouth plaque score API were used to assess local plaque accumulation and compliance. The modified gingival index (mGI) was used to assess the inflammatory state of the soft tissue. The mucositis severity score (MSS) was used to investigate the initiation and progression of peri-implant mucositis, with scores ≥18 indicating advanced inflammation. KM impact on MSS values \<8 and ≥18 was investigated. Periodontal screening index (PSI) was used to classify the general periodontal condition of the patients by dividing the dentition into sextants. The width of the KM mucogingival junction was assessed using the "rolling technique." Radiographs were analyzed using byzznxt to diagnose possible radiological bone resorption. An individual diagnosis was made for each implant at the end of the examination, and data was collected following a standardized operating procedure and saved electronically.
Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
PURPOSE:To provide a safe and useful pharmaceutical composition containing DELTA<1>-pyrroline as an active component, capable of being transferred into the brain in a short time after administration and converted to gamma-aminobutyric acid, and exhibiting the suppressing effect to the central nervous system without using a gamma-aminobutyric acid metabolism inhibitor, etc. having side effects. CONSTITUTION:The objective composition contains DELTA<1>-pyrroline of formula I as a main component. The compound of formula I can be prepared by hydrolyzing 4-aminobutylaldehyde diethyl acetal of formula II with hydrochloric acid, and at the same time, dehydrating the resultant 4-aminobutylaldehyde and amino group. Dose: 200-1,200mg daily preferably by oral administration. The compound of formula II which is a precursor of the active component of formula I is converted to the compound of formula I in the body by oral administration and exhibits suppressing effect on the central nervous system. The compound of formula IIis preferably administered at a dose of 400-240mg daily by oral administration.
This research study seeks to understand how stress reduction training influences neural responses (brain activation) and behavior related to stress, including emotions, desires, and reactions to adverse events such as social conflict. The full research project will be conducted over approximately 4-6 weeks, and will consist of two data collection sessions on the Virginia Commonwealth University (VCU) campus, one before and one after a 14-day stress reduction training course conducted via mobile phone (SmartPhone). The two courses entail instructor-facilitated stress reduction exercises previously shown to reduce stress and improve well-being. Participants will be randomly assigned to a mindfulness course or an active coping course. Both of these courses - mindfulness training (MT) and coping training (CT) - involve expert-facilitated mental wellness techniques. MT emphasizes mindfulness-based techniques to reduce stress and promote well-being, whereas CT emphasizes established emotion regulation techniques to reduce stress and promote well-being.

Some study details are purposely omitted at this time to preserve scientific integrity.
PURPOSE: Cancer of unknown primary (CUP) is a syndrome comprising metastatic cancers without a clinically identified primary site. Although patients with CUP have an unfavorable prognosis, treatment with site-specific therapies guided by clinical features, standard pathology, and molecular assays can improve overall survival. The 92-gene assay (CancerTYPE ID) is a gene expression-based classifier that helps identify the tissue of origin for metastatic cancers with unknown or uncertain diagnoses. This study reports the frequency of selected molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF, in patients with CUP in the MOSAIC database to highlight potential treatment options.
METHODS: MOSAIC is a database of patients with CUP submitted for CancerTYPE ID testing and NeoTYPE biomarker testing. Tumor biopsy samples were analyzed by CancerTYPE ID for tumor type identification and further tested for molecular aberrations of oncogenes, including KRAS, IDH1/2, BRCA1/2, and BRAF.
RESULTS: CancerTYPE ID identified a specific tumor type in 92.5% (2,929 of 3,168) of CUP cases in the MOSAIC database. The most commonly identified histological type was adenocarcinoma (75.4%), with pancreaticobiliary being the most common molecularly diagnosed cancer (24.9%). Aberrations in KRAS, IDH1/2, BRCA, and BRAF genes were identified in 18.8% (n = 597) of biopsies. A cancer-specific US Food and Drug Administration (FDA)-approved or investigational targeted therapy was potentially available for 24.6% (n = 147) of these patients.
CONCLUSION: This retrospective analysis supports incorporating CancerTYPE ID into the evaluation for patients with CUP to help determine the tissue of origin and identify actionable genetic alterations. This approach may allow more patients with CUP to benefit from site-specific FDA-approved targeted therapies or enrollment into clinical trials.
OBJECTIVE: characterize delayed hematuria (DH) after photoselective vaporization of the prostate (PVP) and identify its associated risk factors.
METHODS: 1014 patients who underwent PVP at an expert center, from September 2005 through December 2021, were prospectively enrolled in a database registry. Risk factors of DH included age, prostate volume, ASA score, history of BPH surgery, history of prostate cancer, use of anticoagulation or 5ARIs, concomitant procedure, operative factors, and the duration of follow-up.
RESULTS: The median operating time was 60 ± 11 min. The median specific applied energy was 318,500 Joules ± 101,347. After PVP, the mean catheterization duration was 1.6 days with a postoperative hospitalization time of 1.8 days. The median follow-up was 52 months (range 2-95 months). Hematuria occurred in 206 patients (20.3%), with 10% requiring an ER visit and 8.3% requiring hospital admission, transfusion or endoscopic clot removal. Almost 80% of hematuria episodes occurred within the first 3 months. The overall retreatment rate for clot retention was 3.7% after a mean time of 50 months. Hematuria-free survival was 97.2% after 1 year, and 89.3% after 4 years. Delayed hematuria occurred in 32 patients (3.1%). In the multivariate analysis, age, preoperative prostate volume, anticoagulant use, total applied energy, lasing time and operative time were identified as risk factors for delayed hematuria after PVP.
CONCLUSION: Larger prostate volume, longer operative time, longer lasing time, and use of oral anticoagulation increase the odds of delayed hematuria after PVP, while older age is protective.
Introduction: in previous studies, obesity was identified as a risk factor for inflammatory breast disease, but its causality is uncertain. In the present study, we performed a two-sample Mendelian randomization (TSMR) analysis to investigate the causal relationship between obesity and inflammatory breast disease. Methods: we use body mass index (BMI) as a measure of obesity. Data for single nucleotide polymorphisms (SNPs) associated with BMI were obtained from UK Biobank. Data for single nucleotide polymorphisms (SNPs) associated with mastitis were obtained from FinnGen Biobank. We used several MR analysis methods, such as inverse-variance weighting (IVW), MR-Egger, weighted median, simple mode and weighted mode to make our results more convincing. We also performed MR-PRESSO test, MR-Egger test, heterogeneity test, pleiotropy test and leave-one-out analysis to make our analysis results more robust and credible. We used odds ratio (OR) to evaluate the causal relationship between BMI and mastitis. Results: based on the IVW random effects model, we found that a one-standard deviation (SD) increase in BMI increased the risk of mastitis by 62.1 % (OR = 1.621, 95 % CI: 1.262-2.083, p = 1.59E-4), which is almost consistent with the results of several other methods. Conclusions: in European individuals, an increase in the number of BMI increases the risk of inflammatory breast disease. People with high BMI need to control their weight to reduce the incidence of inflammatory breast disease.
PROBLEM TO BE SOLVED: To provide a film-forming agent which is applied to various objects for the purposes of vibrationproofing, durability, thermal insulation, etc. SOLUTION: This agent contains an animal- or vegetable-derived oil or fat and seaweed-derived component. In one embodiment, this agent comprises a binder fat and gloiopeltis glue in the form of crystalline particles. When used, this agent acts in a manner changing with the state of water retention, while cleaning contaminants on the surface of an object being coated. Thus, a uniform film is formed, which is resistant to vibration in use, shrinkage due to temp. difference, oxidative degradation, peeling, etc. When this agent contains mica particles as a reinforcement, it acts as an abrasive. When it contains thin hairs, it entangles with the hairs and exhibits a chaining function. When dissolved in a water vessel, it functions as a suspended paste to be formed into a film.